Women's Health

On March 26, the Supreme Court heard oral arguments regarding the accessibility, efficacy and safety of mifepristone, a drug commonly used for medication abortion.

Pelvic floor muscle training improved reported sexual function for women with pelvic floor dysfunction, but uncertainties with specific sexual dysfunctions and exact dosing remain, according to researchers.

The HHS has released guidance regarding the requirement for hospitals to obtain informed patient consent before performing sensitive examinations.

Sources for contraception differed among adolescents and young adults based on sociodemographic factors such as insurance status, age and residential area, according to a research letter published in JAMA Pediatrics.

Distribution of medication for self-managed abortion from sources outside of formal health care settings increased 6 months after the Dobbs decision, despite state-level bans and restrictions, according to findings published in JAMA.

Exclusive breastfeeding for at least 3 months was associated with reduced childhood hematologic cancer risk vs. shorter breastfeeding durations, according to cohort study results published in JAMA Network Open.

On March 18, President Joe Biden signed an executive order and announced new actions to improve women’s health research and innovation in the U.S., according to a White House press release.

Since the Dobbs decision in June 2022, mifepristone has been heavily discussed within legal landscapes regarding its safety, efficacy and availability for women seeking medication abortion.

Teen pregnancy may be an indicator for future premature mortality risk in early adulthood up to age 25 years, according to cohort study results published in JAMA Network Open.

Urinary glyphosate concentrations were significantly increased for pregnant women living near agriculture fields during the pesticide spray season of May to August, according to study results published in Environmental Health Perspectives.